With two monotherapy candidates having reached Phase III in non-alcoholic steatohepatitis (NASH), combination therapy is driving the next wave of business development activity for the liver disease, as shown by the tie-up announced April 11 between Tobira Therapeutics Inc. and Dong-A Pharmaceutical Co. Ltd.
Tobira has cenicriviroc (CVC), which it bills as the only NASH candidate that addresses both inflammatory and fibrotic pathways of the disease, in Phase IIb